Antibiotics and inflammatory bowel diseases

Digestive Diseases

Volumn 31, Issue 3-4, 2013, Pages 379-384

  Scribano, Maria Lia ^a   Prantera, Cosimo ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Antibiotics; Crohn's disease; Gut microbiota; Inflammatory bowel disease

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; DAPSONE; ETHAMBUTOL; ISONIAZID; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; NITROIMIDAZOLE; ORNIDAZOLE; PLACEBO; PREDNISOLONE; PYRIMETHAMINE; RIFABUTIN; RIFAMPICIN; RIFAXIMIN; SALAZOSULFAPYRIDINE; SULFADOXINE; ANTIINFECTIVE AGENT;

ADD ON THERAPY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ATYPICAL MYCOBACTERIUM; BACTERIAL FLORA; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; GASTROINTESTINAL DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INTESTINE FLORA; META ANALYSIS (TOPIC); METALLIC TASTE; MICROBIAL ACTIVITY; MYCOBACTERIUM PARATUBERCULOSIS; NEUROTOXICITY; PARATUBERCULOSIS; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REMISSION; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; ABNORMAL LABORATORY RESULT; CLINICAL PRACTICE; DRUG SPECIFICITY; DYSBIOSIS; INFLAMMATORY BOWEL DISEASE; LONG TERM CARE; MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS; NONHUMAN; POSTOPERATIVE COMPLICATION; CHEMICALLY INDUCED; INFLAMMATORY BOWEL DISEASES; MICROBIOLOGY; PATHOLOGY;

ANTI-BACTERIAL AGENTS; DYSBIOSIS; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84888260545     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000354704     Document Type: Conference Paper

References (56)

1. Sartor RB: Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134: 577-594.
2. De Hertogh G, Aerssens J, Geboes KP, Geboes K: Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease. World J Gastroenterol 2008; 14: 845-852.
3. Chassaing B, Darfeuille-Michaud A: The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1720-1728.
4. Card T, Logan RFA, Rodrigues LC, Wheeler JG: Antibiotic use and the development of Crohn's disease. Gut 2004; 53: 246-250.
5. Gilat T, Hacohen D, Lilos P, Langman MJ: Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand J Gastroenterol 1987; 22: 1009-1024.
6. Wurzelmann JI, Lyles CM, Sandler RS: Childhood infections and the risk of inflammatory bowel disease. Dig Dis Sci 1994; 39: 555-560.
7. Hildebrand H, Malmborg P, Askling J, Ekbom A, Montgomery SM: Early-life exposure associated with antibiotic use and risk of subsequent Crohn's disease. Scand J Gastroenterol 2008; 43: 961-966.
8. Hviid A, Svanstrom H, Frisch M: Antibiotic use and inflammatory bowel diseases in childhood. Gut 2011; 60: 49-54.
9. Rutgeerts P, Geboes K, Peeters M, Hiele M, Penninckx F, Aerts R, Kerremans R, Vantrappen G: Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338: 771-774.
10. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-267.
11. Elliot PR, Burnham WR, Berghouse LM, Lennard-Jones JE, Langman MJ: Sulphadoxinepyrimethamine therapy in Crohn's disease. Digestion 1982; 23: 132-134.
12. Shaffer JL, Hughes S, Linaker BD, Baker RD, Turnberg LA: Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut 1984; 25: 203-205.
13. Basilisco G, Ranzi T, Campanini C, Piodi L, Bianchi PA: Controlled trial of rifabutin in Crohn's disease. Curr Ther Res 1989; 46: 245-250.
14. Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP: Controlled trial of antimycobacterial therapy in Crohn's disease: clofazimine versus placebo. Dig Disc Sci 1991; 36: 449-453.
15. Swift GL, Srivastava ED, Stone R, Pullan RD, Newcombe RG, Rhodes J, Wilkinson S, Rhodes P, Roberts G, Lawrie BW, et al: Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut 1994; 35: 363-368.
16. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C: Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind, trial with a multiple antibiotic regimen. Am J Gastroenterol 1994; 89: 513-518.
17. Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P, Mitchell B, Connell W, Read R, Merrett M, Ee H, Hetzel D; Antibiotics in Crohn's Disease Study Group: Twoyear combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132: 2313-2319.
18. Peyrin-Biroulet L, Neut C, Colombel JF: Antimycobacterial therapy in Crohn's disease: game over Gastroenterology 2007; 132: 2594-2598.
19. Lipton JE, Barash DP: Flawed Australian CD study does not end MAP controversy. Gastroenterology 2007; 133: 1742.
20. Kuenstner JT: The Australian antibiotic trial in Crohn's disease: alternative conclusions from the same study. Gastroenterology 2007; 133: 1742-1743.
21. Gitlin L, Biesecker J: Australian Crohn's antibiotic study opens new horizons. Gastroenterology 2007; 133: 1743-1744.
22. Chamberlin W: Importance of the Australian Crohn's disease antibiotic study. Gastroenterology 2007; 133: 1744-1745.
23. Prantera C: Mycobacteria and Crohn's disease. The endless story. Dig Liver Dis 2007; 39: 452-454.
24. Abraham C, Medzhitov R: Interaction between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 2011; 140: 1729-1737.
25. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54.
26. Sasaki M, Sitaraman SV, Babbin BA, et al: Invasive Escherichia coli are a feature of Crohn's disease. Lab Invest 2007; 87: 1042-1054.
27. Barnich N, Darfeuille-Michaud A: Adherentinvasive Escherichia coli and Crohn's disease. Curr Opin Gastroenterol 2007; 23: 16-20.
28. Subramanian S, Roberts CL, Hart CA, et al: Replication of colonic Crohn's disease mucosal Escherichia coli isolated within macrophages and their susceptibility to antibiotics. Antimicrob Agents Chem 2008; 52: 427-434.
29. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottiere HM, Dore J, Marteau P, Seksik P, Langella P: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn's disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-16736.
30. Rogler G: The effect of NOD2/CARD15 mutations on the function of the intestinal barrier. J Crohns Colitis 2007; 1: 53-60.
31. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH: Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol 1995; 102: 448-455.
32. Prantera C: What role do antibiotics have in the treatment of IBD Nat Clin Pract Gastroenterol Hepatol 2008; 5: 670-671.
33. Prantera C, Scribano ML: Antibiotics and probiotics in IBD: why, when, and how. Curr Opin Gastroenterol 2009; 25: 329-333.
34. Scribano ML, Prantera C: Use of antibiotics in the treatment of Crohn's disease. World J Gastroenterol 2013; 19: 648-653.
35. Leiper K, Martin K, Ellis A, Watson AJ, Morris AI, Rhodes JM: Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. Aliment Pharmacol Ther 2008; 27: 1233-1239.
36. Ursing B, Kamme C: Metronidazole for Crohn's disease. Lancet 1975;i:775-777.
37. Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, Hoevels J, Huitfeldt B, Jarnerot G, Krause U, Krook A, Lindstrom B, Nordle O, Rosen A: A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the Cooperative Crohn's Disease Study in Sweden. II. Result. Gastroenterology 1982; 83: 550-562.
38. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M, Levine J, Thomson A, Alpert E, Prokipchuk E: Double-blind, placebo-controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-1075.
39. Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, Notteghem B, Mary JY: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d' Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999; 94: 674-678.
40. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ: Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002; 8: 10-15.
41. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzi C: An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328-332.
42. Greenbloom SL, Steinhart AH, Greenberg GR: Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 1998; 12: 53-56.
43. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greenberg GR: Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002; 123: 33-40.
44. Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD: Incidence of C lostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339-344.
45. Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, Emmons J, Bajaj JS, Binion DG: Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-351.
46. Ananthakrishan AN, McGinley EL, Binion DG: Excess hospitalization burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57: 205-210.
47. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M: Antibiotic treatment of Crohn's disease: results of a multicentre, double-blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006; 23: 1117-1125.
48. Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P; Retic Study Group (rifaximin-EIR Treatment in Crohn's Disease): Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 142: 473-481.
49. Patrick Basu P, Dinani A, Rayapudi K, Pacana T, Shah NJ, Hampole H, Krishnaswamy NV, Mohan V: Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Ther Adv Gastroenterol 2010; 3: 221-225.
50. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R: Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-1621.
51. Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, Aerden I, De Hertogh G, Geboes K, Hiele M, D'Hoore A, Penninckx F: Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128: 856-861.
52. D'Haens G, Vermeire S, Van Assche G, Noman M, Aerden I, Van Olmen G, Rutgeerts P: Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008; 135: 1123-1129.
53. Rahimi R, Nikfar S, Rezaie A, Abdollahi M: A meta-analysis of broad spectrum antibiotic therapy in patients with active Crohn's disease. Clin Ther 2006; 28: 1983-1988.
54. Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M: Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis 2010; 50: 473-480.
55. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P: Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 661-673.
56. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollon F, Hommes DW, Michetti P, O'Morain C, Oresland T, Windsor A, Stange EF, Travis SP; European Crohn's and Colitis Organisation (ECCO): The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.